HER2-Negative Breast Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Genentech, CytomX Therapeutics, H3 Biomedicine, Regor Therapeutics, Immutep Limited, Mer

HER2-Negative Breast Cancer Pipeline constitutes 70+ key companies continuously working towards developing 75+ HER2-Negative Breast Cancer treatment therapies, analyzes DelveInsight.

HER2-Negative Breast Cancer Overview:

Breast cancer is the most prevalent disease among women worldwide and a leading cause of death. Reports indicate that 5% of patients with breast cancer are diagnosed with distant metastasis, and 30% of those with early-stage cancer will later develop metastatic disease. Although metastatic breast cancer is not curable, survival rates have improved with the advent of new therapies. The aim of treatment is to extend the survival of patients and enhance their quality of life by managing cancer-related symptoms. Treatments should be personalized for each patient, rather than adopting a one-size-fits-all approach. HER2-negative breast cancer refers to cases where the cancer cells do not have high levels of the HER2 protein, which is typically involved in regulating the growth and repair of healthy breast tissue.

There are various treatment options available for HER2-negative breast cancer, though outcomes can vary. The term "HER2" refers to the human epidermal growth factor receptor 2, either as a gene or the protein it produces. These proteins sit on the surface of breast cells and are responsible for controlling the growth of healthy tissue. HER2-negative breast cancer is generally categorized into two types based on the presence or absence of hormone receptors: hormone receptor-positive (HR-positive) and triple-negative breast cancer. In cases of HER2-negative advanced (metastatic) breast cancer, treatment focuses on managing the disease, rather than curing it. The primary goal is to help patients live longer, with a better quality of life.

Treatment for this type of cancer often involves systemic therapies, which circulate through the bloodstream to target cancer cells in various parts of the body. Hormonal therapy is commonly the first treatment for HR-positive advanced breast cancer, which occurs in 50%-70% of cases. This type of cancer is influenced by hormones like estrogen or progesterone, which promote cancer growth. Hormonal therapies either lower estrogen levels or prevent estrogen from binding to cancer cells, hindering their ability to grow. These therapies typically have fewer severe side effects compared to chemotherapy. Chemotherapy, which uses various drugs alone or in combination, is another common treatment for HER2-negative breast cancer. Targeted therapies are also being researched to block specific proteins or molecules that contribute to cancer growth and spread. These molecules are the "targets" of the drugs, and research into these therapies is ongoing.

Request for a detailed insights report on HER2-Negative Breast Cancer pipeline insights @ https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"HER2-Negative Breast Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the HER2-Negative Breast Cancer Therapeutics Market.

Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report

DelveInsight's HER2-Negative Breast Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for HER2-Negative Breast Cancer treatment.
In January 2025, DATROWAY® was approved in the U.S. for patients with previously treated metastatic HR-positive, HER2-negative breast cancer. The U.S. Food and Drug Administration (FDA) approved DATROWAY® based on the results of the TROPION-Breast01 phase 3 trial. In the trial, DATROWAY reduced the risk of disease progression or death by 37% compared to the investigator's choice of chemotherapy (hazard ratio [HR]=0.63; 95% confidence interval [CI]: 0.52-0.76; p

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.